Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

Saved in:
Bibliographic Details
Main Authors: Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC
Format: article
Language:EN
Published: Elsevier 2022
Subjects:
biologic
efficacy
IL-23
inhibitor
psoriasis
risankizumab
Dermatology
RL1-803
Online Access:https://doaj.org/article/e5569883aea8428a970c97f32babd322
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/e5569883aea8428a970c97f32babd322

Similar Items